These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 15587640)
21. [The inspection of information: "Hidden" comparison, words of evaluation often cause notifications]. Lakartidningen; 1996 Aug; 93(32-33):2763-5. PubMed ID: 8765603 [No Abstract] [Full Text] [Related]
22. [To listen without wasting time]. Bosnes V Tidsskr Nor Laegeforen; 1999 Mar; 119(8):1195. PubMed ID: 10228428 [No Abstract] [Full Text] [Related]
23. [The Board for Evaluation of Drug Information: "Cognex clinics" are not popular. Guidelines for a new type of information]. Lakartidningen; 1997 Jan; 94(1-2):32. PubMed ID: 9053600 [No Abstract] [Full Text] [Related]
24. [Views on marketing of a neuroleptic agent]. Bendz H Lakartidningen; 1999 Nov; 96(47):5191-2. PubMed ID: 10608107 [No Abstract] [Full Text] [Related]
25. More on the pharmaceutical quagmire. Schlemmer JP Fam Med; 1993; 25(7):429-30. PubMed ID: 8292144 [No Abstract] [Full Text] [Related]
26. [Reporting by the IGM (Information Inspection Team). Marketing of Clarityn disguised as an inquiry]. Lakartidningen; 1996 Sep; 93(37):3168. PubMed ID: 8847942 [No Abstract] [Full Text] [Related]
28. [Strange reaction to drug therapy]. Aarbakke J; Rasmussen K Tidsskr Nor Laegeforen; 2003 Jun; 123(13-14):1910. PubMed ID: 12830285 [No Abstract] [Full Text] [Related]
29. [Is household-targeted Gardasil advertising in accordance with the intentions of the legislators?]. Linnersten L Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2121. PubMed ID: 18751457 [No Abstract] [Full Text] [Related]
30. [Can we rely on drug information?]. Myhr K Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2644-6. PubMed ID: 12523198 [No Abstract] [Full Text] [Related]
31. [Pharmaceutical informations. 3. Drug information (supplementary pamphlet-scientific pamphlet)]. Kohlstaedt E Med Welt; 1969 Jul; 28():1579-81. PubMed ID: 5810236 [No Abstract] [Full Text] [Related]
33. [Drug information from the producers]. Lund H Tidsskr Nor Laegeforen; 2001 Feb; 121(5):550. PubMed ID: 11301605 [No Abstract] [Full Text] [Related]
34. [Generic preparations are a nuisance]. Lyftingsmo S Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1802-3. PubMed ID: 17599134 [No Abstract] [Full Text] [Related]
35. ASHP policy on the acceptance of advertising. Am J Hosp Pharm; 1992 Jan; 49(1):160-1. PubMed ID: 1442809 [No Abstract] [Full Text] [Related]
36. [Written drug advertisements--are they reliable?]. Solhaug HR; Indermo H; Slørdal L; Spigset O Tidsskr Nor Laegeforen; 2006 May; 126(10):1314-7. PubMed ID: 16691265 [TBL] [Abstract][Full Text] [Related]
37. [Pharmaceutical advertising and scientific papers versus dermatology and venerology]. László A; Micánek B; Oser M Hautarzt; 1970 Jan; 21(1):32-3. PubMed ID: 5538160 [No Abstract] [Full Text] [Related]
38. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
39. [Physicians report verbal drug information. Cases scrutinized by the IGM]. Perman E Lakartidningen; 2004 Aug; 101(35):2648, 2650. PubMed ID: 15458219 [No Abstract] [Full Text] [Related]
40. [What can we learn from the marketing of TrioBe?]. Svensson S; Mellén A Lakartidningen; 2007 Feb 28-Mar 6; 104(9):690. PubMed ID: 17393869 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]